Q&A With Levi Garraway, MD, PhD, on Hot Topics at the International Conference on Molecular Targets and Cancer Therapeutics

Levi Garraway, MD, PhD, co-chair of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston Nov. 5-9, provides insights into the meeting.

Read More

Overcoming Drug Resistance: The EGFR Enigma

Currently, anti-EGFR therapies are approved by the U.S. Food and Drug Administration for the treatment of non-small cell lung cancer, squamous cell carcinoma of the head and neck, pancreatic cancer, and colorectal cancer. Most patients receiving anti-EGFR therapies benefit from the treatment, but the challenge they face, as do patients receiving most other targeted therapies, is that their tumors ultimately develop drug resistance. So efforts are underway to develop newer anti-EGFR therapies that can circumvent resistance to existing EGFR inhibitors.

Read More